New research advances an Epstein–Barr virus vaccine, while another study detects higher levels of microplastics in prostate cancer tumors.

A Study shows mutation-resistant antibodies with 269×affinity, a proof point for CEPI’s 100 Days Mission and closing ...

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, ...

Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript March 5, 2026 Invivyd, Inc. misses on earnings expectations. Reported EPS is $-0.06428 EPS, expectations were $-0.06. Operator: Good day, ...

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy ...

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

Researchers engineer CAR-astrocytes to target and remove amyloid plaques in Alzheimer’s, showing a 50% reduction in brain ...

Accelerated review was enabled by the Commissioner’s National Priority Voucher Pilot Program, targeting high unmet need and compressing FDA action to 1–2 months with enhanced reviewer communication.

Invivyd, which focuses on protection against viral infectious diseases, is naming Michael Mina, MD, PhD, chief medical officer.

Slate Medicines, a new Raleigh biotechnology company developing treatments for migraine and headache disorders, has announced ...

Elia addressed the DECLARATION study for VYD2311: "We were recently notified that the DECLARATION clinical trial has reached target enrollment...may modestly over enroll as sites are permission to ...

NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business ...